What is happening, page-3199

First 3199 Last

Share
Profile

Follow
Tizard

1,117 Posts.

143

29/03/24

16:56

Post #: 73119228
Share

Originally posted by Geeris: ↑

You make some great points Tizard.

I would like to add some further points to the discussion -

AXE had 17 employees in January. EPFL has 6000 and over 11 000 students, over 1000 phD students.
So the EPFL partnership is great for us.AXE paid for part of this p-ESR development. The development was necessary for low voltage, low noise detection of spin manipulations which is how a 12CQ device will have a more viable way to control and read out in a noisy encironment. It is most definitely a 12CQ development milestone for us and a further de-risking of the 12CQ project. Adds to the value of the 12CQ IP. Eyes firmly on the end goal of a working device. Mo has clearly stated it advances the 12CQ. So we have built one additional component of a 12CQ device.

The added potential uses for the p-ESR in miniaturised spectrometers and precision sensing is something that EPFL can run with. Plenty of students there to work on designing ASICs with the p-ESR embedded. It could potentially earn something. AXE will get a share of it if it eventuates down the track.

and being a fabless company, we have to partner with foundries to make the chips we design, test it and package it. We will have to pay TSMC, we can also have partners like the Japanese testing and packaging company.

Speaking of fabless semiconductor companies, one of Mo's favourite ways to describe AXE, a more understandable comparison is with Qualcomm. Their Snapdragon chips are in our Android phones. They own IPs on many other chips used in cars to aviation. They have 50k employees.

If we want a quantum company to compare with, Diraq is an Australian quantum company. Develops spin qubits with CMOS. To date it has had to raise USD 120 million for its work. They manage with about 30 post doctoral staff spread across the globe.

AXE doesn't yet fit into fabless or quantum company structures yet. It does though seem to be going more the partnership route at every turn to leverage other institutions' and companies' resources.

Expand

Thanks for the clarification @Geeris, paints a clearer picture of how AXE interact with those they need to further their end game. As a matter of interest there would have to be contracts in place for these agreements do you know if the terms of those contracts are readily available or is that something ive missed in previous Company announcements
Cheers

AXE Price at posting: 57.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

There are more pages in this discussion • 555 more messages in this thread...

First 3199 Last

Add AXE (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change 0.040(18.6%)		Mkt cap ! $64.98M

Open	High	Low	Value	Volume
22.0¢	26.0¢	22.0¢	$230.2K	956.6K

Buyers (Bids)

No.	Vol.	Price($)
1	4166	24.0¢

Sellers (Offers)

Price($)	Vol.	No.
25.5¢	3500	1

View Market Depth

No.	Vol.	Price($)
1	4166	0.240
2	26276	0.235
2	27200	0.230
1	3574	0.225
3	65946	0.220

Price($)	Vol.	No.
0.255	3500	1
0.260	3800	1
0.265	40481	4
0.270	57000	5
0.275	15000	1

Last trade - 15.56pm 07/10/2024 (20 minute delay)

AXE (ASX) Chart

What is happening, page-3199

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

What is happening, page-3199

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News